NEW YORK, August 9, 2026, 18:20 (EDT).
Doximity Inc NYSE:DOCS shares climbed 32.6% to $27.40 on Friday but ended the session 31.5% under its intraday peak of $40.
Doximity shares started trading at $38.86 and then dropped 29.5% by the end of the session. Trading volume hit 65.32 million shares, 16.4 times the daily average. Market action indicated investors reassessed Doximity’s AI momentum but dismissed the initial pricing.
| Friday tape | Value | Investor read-through |
|---|---|---|
| Previous close | $20.66 | Reference point before results |
| Open | $38.86 | Opened 88.1% higher than previous close |
| Intraday high | $40.00 | Highest price during the session |
| Close | $27.40 | Up 32.6% on the day |
| Close versus high | -31.5% | Notable swing from session high |
| Volume | 65.32 million | Traded 16.4 times usual volume |
Doximity outperformed two public digital-health rivals. Teladoc Health Inc NYSE:TDOC advanced 6.7%, and American Well Corp (NYSE:AMWL) climbed 4.6%.
The surge occurred without a wide-based increase in profits. Revenue for the fiscal first quarter rose 7%, yet net income decreased by 54%. Adjusted EBITDA was down 6%, and free cash flow slid 34%.
| Fiscal Q1 metric | Fiscal 2027 Q1 | Fiscal 2026 Q1 | Change |
|---|---|---|---|
| Revenue | $156.6 million | $145.9 million | +7% |
| Net income | $24.3 million | $53.3 million | -54% |
| Adjusted EBITDA | $74.8 million | $79.8 million | -6% |
| Free cash flow | $39.6 million | $60.1 million | -34% |
| Net margin | 15.5% | 36.5% | -21.0 points |
| Adjusted EBITDA margin | 47.7% | 54.7% | -7.0 points |
AI usage provided balance for the company. “AI Search query growth of over 25% quarter-over-quarter,” Chief Executive Jeff Tangney noted. The number of workflow active prescribers rose upwards of 30% compared to the previous year. U.S. Securities and Exchange Commission
For the full fiscal year, May’s initial guidance forecast revenue between $664 million and $676 million, with adjusted EBITDA expected in the range of $323 million to $335 million.
| Fiscal 2027 outlook | August 6 update | May 13 outlook | Midpoint change |
|---|---|---|---|
| Revenue | $671 million-$681 million | $664 million-$676 million | +0.9% |
| Adjusted EBITDA | $309 million-$329 million | $323 million-$335 million | -3.0% |
The August revision raised the revenue midpoint to $676 million, while the adjusted EBITDA midpoint was reduced to $319 million. For the second quarter, the company expects revenue between $170 million and $171 million.
Analyst notes released on Friday continued to reflect wide-ranging views. Four firms raised their price targets but maintained ratings between Outperform and Market Perform.
| Firm | Recommendation | Target change | Versus $27.40 close |
|---|---|---|---|
| Piper Sandler | Overweight | $42 to $47 | +71.5% |
| Evercore ISI | In Line | $22 to $40 | +46.0% |
| Raymond James | Outperform | $23 to $38 | +38.7% |
| BMO Capital | Market Perform | $20 to $30 | +9.5% |
The average price target from 21 analysts at S&P Global stood at $29.41, representing a 7.3% premium to Friday’s closing price. Of those analysts, nine rated the stock as Strong Buy or Buy, 11 advised Hold, and one assigned a Sell recommendation.
Markets face two key tests in the coming week. July’s consumer price figures are due Wednesday, and producer price data follow on Thursday. Both reports are set for release at 08:30 EDT.
Risks are still centered on conversion rates and profit margins. Increased use of AI might not lead to equal revenue gains, and weaker cash flow further reduces the financial buffer. Missing the $170 million second-quarter revenue threshold would put Friday’s rerating in question.
Related articles: NYSE:DOCS
